Gencor’s Levagen+ may help migraine sufferers

Published: 9-Feb-2024

A palmitoylethanolamide (PEA) ingredient, Levagen+ has proven to be a safe and effective supplement for reducing discomfort and duration of migraines in healthy participants

Gencor has announced the publication of its recent human clinical trial demonstrating that Levagen+ is safe and effective supplement for reducing discomfort and duration of migraines in healthy participants. 

Migraines are a common neurological disorder affecting young to middle-aged adults, with women more statistically likely to suffer than men. Various treatment options are available, but many cause undesirable side effects. PEA has been clinically studied to support a healthy inflammatory response and its analgesic properties. 

The double-blind, placebo-controlled clinical trial, published in the leading Pharmaceuticals journal, investigated the effectiveness of pain reduction, duration and medication use during a migraine.

Upon the commencing of migraine symptoms, study participants were either given 600mg of PEA (Levagen+) or a placebo (maltodextrin). 

Once the dose was taken, participants recorded a visual analog scale (VAS) for pain every 30 minutes for 4 hours or until the migraine resolved.

If the migraine had not resolved 2 hours post-dose, study participants were instructed to take a second supplement. 

The study demonstrated that Levagen+ resolved more headaches than the placebo after 2 and 8 hours. The Levagen+ participants also had a lower VAS for pain score at 1.5 and 4 hours and significantly reduced rescue medication compared to the placebo.

“The results of this study further back PEA’s clinically validated benefits for its analgesic and inflammatory properties in addition to its neuroprotective effects,” said R.V. Venkatesh, Co-founder and Managing Director at Gencor. “We are thrilled about the promising results and potential of Levagen+ to support those who suffer from migraine.” 

Levagen®+ is powered by LipiSperse® delivery technology developed by Pharmako Biotechnologies. It offers a functional and bioavailable form of palmitoylethanolamide (PEA) with superior absorption.

Levagen+ is a self-affirmed GRAS ingredient manufactured in cGMP facilities and has been clinically tested to support joint health, sleep, recovery, immunity, discomforts, and inflammation.

Levagen®+ is applicable for dietary supplements, food, beverages and cosmeceuticals.

Relevant companies

You may also like